Literature DB >> 10606817

Multiple mutations of the p53 gene in human mammary carcinoma.

L Meng1, L Lin, H Zhang, M Nassiri, A R Morales, M Nadji.   

Abstract

Alteration of the p53 tumor suppressor gene is the most common genetic abnormality in human cancer. In breast cancer, depending on the stage of disease and method of detection, mutation rates of 25-60% have been observed. Multiple mutations of p53 gene in the same tumor however, are rarely reported. In this study we explored the frequency of multiple mutations of p53 gene in mammary carcinoma in a cohort of south Florida patients. Three hundred eighty-four cases of primary breast cancer diagnosed between 1984 and 1986 at the University of Miami, Jackson Medical Center were subjects of this study. Sequence analysis of exons 5 through 8 of p53 was performed on cloned PCR-amplified DNA of formalin-fixed, paraffin-embedded tumors. Two hundred thirty-four of 384 breast cancers (61%) had p53 mutation. Of those, 36 tumors showed more than one mutation; 31 tumors had two mutations, three showed three, one tumor had five mutations, and one case carried six mutations. The majority of mutations were missense (43) followed by silent (35); and most occurred within a single exon. Our study suggests that multiple mutations of p53 suppressor gene in breast cancer are more common than currently believed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10606817     DOI: 10.1016/s0921-8777(99)00053-1

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  6 in total

Review 1.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

2.  Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases.

Authors:  Kosuke Hashimoto; Igor B Rogozin; Anna R Panchenko
Journal:  Hum Mutat       Date:  2012-07-16       Impact factor: 4.878

Review 3.  Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes.

Authors:  Nayiri M Kaissarian; Douglas Meyer; Chava Kimchi-Sarfaty
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

Review 4.  Molecular mechanisms of disease-causing missense mutations.

Authors:  Shannon Stefl; Hafumi Nishi; Marharyta Petukh; Anna R Panchenko; Emil Alexov
Journal:  J Mol Biol       Date:  2013-07-16       Impact factor: 5.469

5.  Predicting transcriptional activity of multiple site p53 mutants based on hybrid properties.

Authors:  Tao Huang; Shen Niu; Zhongping Xu; Yun Huang; Xiangyin Kong; Yu-Dong Cai; Kuo-Chen Chou
Journal:  PLoS One       Date:  2011-08-08       Impact factor: 3.240

6.  Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.

Authors:  M Michaelis; F Rothweiler; S Barth; J Cinatl; M van Rikxoort; N Löschmann; Y Voges; R Breitling; A von Deimling; F Rödel; K Weber; B Fehse; E Mack; T Stiewe; H W Doerr; D Speidel; J Cinatl
Journal:  Cell Death Dis       Date:  2011-12-15       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.